Toxicity profile of cisplatin given at one full dose versus three divided doses for three consecutive days.

Abstract

e14018Background: Cisplatin has been extensively used as a chemotherapeutical agent for treatment of many types of solid cancers for decades. Although it has been approved for use at 75 mg/m2 q3w,many doctors still prefer to administer cisplatin at divided doses for several days. We undertook this study to compare cisplatin at 75 mg/m2 for patients enrolled in our prospective clinical trials and the drug at 25 mg/m2 for 3 consecutive days for those contemporarily treated in our Hospital in terms of toxicity. Methods: 483 metastatic breast cancer patients who underwent at least one cycle of cisplatin-based combination chemotherapy were included. They received cisplatin 75 mg/m2 on day 1 with three-day hydration, q3w (cisplatin 1-day arm) or cisplatin 25 mg/m2 on day 1-3 with no hydration, q3w (cisplatin 3-day arm). Cisplatin-related adverse events were collected and analyzed, focusing on nephrotoxicity, neutropenia, nausea, vomiting, and serum electrolyte. Results: 256 patients (53.0%) received 3-day cispl...